Investors

corporate profile

Ovid Therapeutics Inc. is a New York-based biopharmaceutical company using its BoldMedicine® approach to develop medicines that transform the lives of patients with rare neurological disorders. Ovid has a broad pipeline of potential first-in-class medicines. The company’s most advanced investigational medicine, OV101 (gaboxadol), is currently in clinical development for the treatment of Angelman syndrome and Fragile X syndrome. Ovid is also developing OV935 (soticlestat) in collaboration with Takeda Pharmaceutical Company Limited for the potential treatment of rare developmental and epileptic encephalopathies (DEE).

stock
snapshot

Additional stock info »

04.1.2020 | 11:46 PM EDT
Copyright West LLC. Minimum 15 minutes delayed.

View all news »

View all events and presentations »

Latest Corporate Presentation Get the Ovid primer— download our latest corporate presentation for investors.

Explore the Ovid Pipeline The Ovid pipeline includes several candidates that would potentially be the first to make a meaningful impact in the lives of individuals with rare neurological conditions. View our pipeline »

Get Investor Updates Have the latest on the BOLD happenings at Ovid, from clinical trial endpoint and data announcements to corporate news, sent right to your inbox. Sign up now »

for investors

Site - Investor Relations - 2nd Tier

Investors